Revumenib

from OncoPharm · host John Bossaer

The 1st menin inhibitor, revumenib, is approved for relapsed/refractory acute leukemias. Understanding the Pathway: https://doi.org/10.1200/JCO-24-01265

Episode metadata supplied by the publisher feed · Published Nov 21, 2024

Embed this episode

Attribution link and audio player

Ready to play

Revumenib

0:00 14:52

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncoPharm?

This episode is 14 minutes long.

When was this OncoPharm episode published?

This episode was published on November 21, 2024.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!